Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action
- 19 March 2021
- journal article
- research article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 35 (4) , 453-458
Abstract
Major depressive disorder (MDD) is among the most prevalent mental health disorders worldwide, and it is associated with a reduced quality of life and enormous costs to health care systems. Available drug treatments show low-to-moderate response in most patients, with almost a third of patients being non-responders (treatment-resistant). Furthermore, most currently available medications need several weeks to achieve therapeutic effects, and the long-term use of these drugs is often associated with significant unwanted side effects and resultant reductions in treatment compliance. Therefore, more effective, safer, and faster-acting antidepressants with enduring effects are needed. Together with ketamine, psychedelics (or classic or serotoninergic hallucinogens) such as lysergic acid diethylamide (LSD), psilocybin, and ayahuasca are among the few compounds with recent human evidence of fast-acting antidepressant effects. Several studies in the 1950s to 1970s reported antidepressive and anxiolytic effects of these drugs, which are being confirmed by modern trials (LSD, one trial; psilocybin, five trials; ayahuasca, two trials). The effects of these drugs appear to be produced primarily by their agonism at serotonin (5-hydroxytryptamine, 5-HT) receptors, especially the 5-HT2A receptor. Considering the overall burden of MDD and the necessity of new therapeutic options, the promising (but currently limited) evidence of safety and efficacy of psychedelics has encouraged the scientific community to explore more fully their beneficial effects in MDD.Keywords
Funding Information
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
This publication has 56 references indexed in Scilit:
- The drugs don’t work? antidepressants and the current and future pharmacological management of depressionTherapeutic Advances in Psychopharmacology, 2012
- Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trialsJournal of Psychopharmacology, 2012
- Neural correlates of the psychedelic state as determined by fMRI studies with psilocybinProceedings of the National Academy of Sciences of the United States of America, 2012
- Intrahippocampal LSD accelerates learning and desensitizes the 5-HT2A receptor in the rabbit, Romano et al.Psychopharmacology, 2010
- Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime membersJournal of Ethnopharmacology, 2007
- Behavioral Tolerance to Lysergic Acid Diethylamide is Associated with Reduced Serotonin-2A Receptor Signaling in Rat CortexNeuropsychopharmacology, 2005
- HallucinogensPharmacology & Therapeutics, 2004
- Role of the Serotonin 5-HT2AReceptor in LearningLearning & Memory, 2003
- Psychedelic and Entactogenic Drugs in the Treatment of DepressionJournal of Psychoactive Drugs, 1994
- LSD RevisitedArchives of General Psychiatry, 1971